March 18, 2024 — SS Innovations International, Inc. is a developer of innovative surgical robotics technology dedicated to making world-class robotic surgery affordable and accessible to people around the world. Today, surgeons announced they have successfully performed the world’s first mitral valve replacement using Made. In India, SSi Mantra surgical robotic system. The procedure, performed at the Narayana Hrudayalaya Institute of Cardiac Sciences in Bangalore, India, marks a breakthrough in the treatment of heart disease using the SSi Mantra Surgical Robotic System.

The mitral valve surgery was performed by Dr. Nitin Kumar Rajput of the Narayana Institute of Cardiac Sciences in Bengaluru, Karnataka, and by Sudhir Kumar Rajput, founder and chairman of SS Innovations, one of the early pioneers of robotic heart bypass surgery. I was mentored by Dr. Srivastava.

Considering this achievement, Dr. Srivastava commented: “I am extremely proud of our team for pushing the envelope to enable the field of full-spectrum robotic cardiac surgery to be added to all other surgical subspecialties. 90-95% of all cardiac surgeries is still performed today using a large split sternotomy incision. Since our inception, it has always been our goal to meet the need to provide highly minimally invasive solutions for cardiac patients.

“During my practice in the United States, I have noticed that surgical approaches that do not involve tearing the sternum provide significant benefits to patients. Many patients are discharged from the hospital the next day, and after only a week to 10 days, complete recovery of function. The results were impressive. This led me to develop a more complex robotic bypass surgery that was adopted by other surgeons and ultimately This will benefit many more patients undergoing heart surgery.

“We use the Indian-made SSi Mantra surgical robotic system to perform a variety of robotic cardiac surgeries, including bilateral internal mastectomies, fully endoscopic coronary bypass for beating hearts, and atrial septal defect repair. We are very proud to have achieved a completely robotic mitral valve replacement. With the help of extremely talented surgeons at the Narayana Institute of Cardiac Sciences, we were able to achieve our original goal. I am very happy about that.”

Commenting on the successful completion of the surgery, Dr Nitin Kumar Rajput, Consultant Cardiac Surgeon at Narayana Health, who was the lead surgeon for the mitral valve replacement, said: system and we just performed our first robotic mitral valve repair a few days ago. The surgery went perfectly and using the Mantra system was great. Four ports were created for the robot arm and a smaller 2.5 cm working port for the tableside assistant. The surgery was over quickly. The patient had an uneventful postoperative course and was discharged from the hospital 3 days after surgery with good exercise tolerance. ”

Dr. Srivastava said: “SS Innovations is dedicated to improving patient access and optimizing surgical outcomes with accessible and cost-effective surgical robotic systems. We recognize the tremendous opportunity to address the significant unmet need for safe, timely and affordable cardiac surgical care.”

“This groundbreaking procedure is a testament to our commitment to advancing cardiac care. The success of this procedure opens new avenues in the treatment of heart disease and provides patients with a less invasive option. Recovery time is reduced and results are better.”

“SSi Mantra embodies innovation and excellence, delivering unparalleled precision and control in robot-assisted surgery. Today’s success is a proud moment for everyone at SS Innovations and our partners at Narayana Hrudayalaya. ,” concluded Dr. Srivastava.

The mitral valve disease market size was valued at $2.5 billion in 2021 and is estimated to reach $5.7 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031.

The SSi Mantra surgical robotic system is the first surgical robotic system manufactured in India and one of the few cost-effective global options with a wide range of surgical applications and is available in India, Indonesia and Guatemala. It has regulatory approval and is in clinical use. Validated for over 50 different types of surgical procedures. To date, more than 800 surgical procedures have been performed using this system. SS Innovations has begun the regulatory approval process in the US and EU, with approval expected in late 2024 or 2025.

For more information, please visit www.ssinnovations.com.